company background image
JAGSNPHARM logo

Jagsonpal Pharmaceuticals NSEI:JAGSNPHARM Stock Report

Last Price

₹339.85

Market Cap

₹9.0b

7D

-1.3%

1Y

-8.2%

Updated

24 Jun, 2024

Data

Company Financials

Jagsonpal Pharmaceuticals Limited

NSEI:JAGSNPHARM Stock Report

Market Cap: ₹9.0b

JAGSNPHARM Stock Overview

Engages in the manufacture and trading of pharmaceutical products and active pharmaceutical ingredients in the areas in the areas of women health, pain and analgesics, and general medicine in India and internationally.

JAGSNPHARM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends5/6

Rewards

Risk Analysis


Jagsonpal Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jagsonpal Pharmaceuticals
Historical stock prices
Current Share Price₹339.85
52 Week High₹514.85
52 Week Low₹273.60
Beta1.12
11 Month Change-0.67%
3 Month Change23.29%
1 Year Change-8.22%
33 Year Change110.56%
5 Year Change1,199.62%
Change since IPO-49.50%

Recent News & Updates

Recent updates

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06
Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29
Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13
A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05
Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21
Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08
The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21
Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Shareholder Returns

JAGSNPHARMIN PharmaceuticalsIN Market
7D-1.3%-1.7%-0.1%
1Y-8.2%50.6%46.3%

Return vs Industry: JAGSNPHARM underperformed the Indian Pharmaceuticals industry which returned 50.6% over the past year.

Return vs Market: JAGSNPHARM underperformed the Indian Market which returned 46.3% over the past year.

Price Volatility

Is JAGSNPHARM's price volatile compared to industry and market?
JAGSNPHARM volatility
JAGSNPHARM Average Weekly Movement7.2%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.5%
10% most volatile stocks in IN Market9.5%
10% least volatile stocks in IN Market4.3%

Stable Share Price: JAGSNPHARM has not had significant price volatility in the past 3 months.

Volatility Over Time: JAGSNPHARM's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1978940Manish Guptawww.jagsonpal.com

Jagsonpal Pharmaceuticals Limited engages in the manufacture and trading of pharmaceutical products and active pharmaceutical ingredients in the areas in the areas of women health, pain and analgesics, and general medicine in India and internationally. It offers pharmaceutical formulations and over the counter drugs in the areas of gynaecology, orthopaedics, and allergy management. It offers drugs in the form of tablets, softgels, injections, capsules, and syrups.

Jagsonpal Pharmaceuticals Limited Fundamentals Summary

How do Jagsonpal Pharmaceuticals's earnings and revenue compare to its market cap?
JAGSNPHARM fundamental statistics
Market cap₹8.99b
Earnings (TTM)₹224.63m
Revenue (TTM)₹2.09b

40.0x

P/E Ratio

4.3x

P/S Ratio

Is JAGSNPHARM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JAGSNPHARM income statement (TTM)
Revenue₹2.09b
Cost of Revenue₹799.77m
Gross Profit₹1.29b
Other Expenses₹1.06b
Earnings₹224.63m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)8.50
Gross Margin61.68%
Net Profit Margin10.76%
Debt/Equity Ratio0%

How did JAGSNPHARM perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

59%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.